Collaborative Fund Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Collaborative Fund Advisors's NBIX Position: Q3 2026 in Review
Collaborative Fund Advisors reduced its Neurocrine Biosciences (NBIX) stake by 67% in Q3 2026, selling an estimated $715K and leaving 2,165 shares worth $307K. The position accounts for 0.17% of the portfolio, ranked #162.
Collaborative Fund Advisors first reported a position in NBIX in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.11M in Q2 2026. 770 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Collaborative Fund Advisors held 2,165 shares of Neurocrine Biosciences worth $307K as of Q3 2026.
- Collaborative Fund Advisors sold 4,446 Neurocrine Biosciences shares in Q3 2026, an estimated $715K.
- Neurocrine Biosciences made up 0.17% of Collaborative Fund Advisors's portfolio in Q3 2026, its #162 holding.
- Collaborative Fund Advisors first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 3 quarters since.
- Collaborative Fund Advisors's Neurocrine Biosciences position peaked at $1.11M in Q2 2026.
- 770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Collaborative Fund Advisors's 13F filing for Q3 2026, filed 2 Nov 2026.